Last reviewed · How we verify

NCT05836181: EMDR

The Effect of Eye Movement Desensitization and Reprocessing Intervention in Hypertension Patient.

Completed NA Last updated 1 May 2023
What this trial tests

NA trial testing Eye Movement Desensitization and Reprocessing in Eye Movement Desensitization and Reprocessing Intervention in 110 participants. Completed in 28 December 2016.

Timeline
1 February 2014
Primary endpoint
10 December 2016
28 December 2016

Quick facts

Lead sponsorMiao-Yi Chen
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment110
Start date1 February 2014
Primary completion10 December 2016
Estimated completion28 December 2016
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Miao-Yi Chen

Who can join

Adults 20 to 80, any sex, with Eye Movement Desensitization and Reprocessing Intervention or Blood Pressure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Eye Movement Desensitization and Reprocessing intervention may improve anxiety, depression, systolic blood pressure and heart rate variability in patients with hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Eye Movement Desensitization and Reprocessing

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05836181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing